Alembic Ltd

Alembic Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Ltd

₹ 94.4 -0.42%
26 Apr 4:02 p.m.
alembiclimited.com BSE: 506235 NSE : ALEMBICLTD
About

Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.[1]

Key Points

Business Portfolio:
A) Pharmaceuticals:
The company deals in the bulk drugs manufacturing and marketing of APIs like Estolate, Biphenyl Valine Oxalate, Venlafaxine, etc. AL is also engaged in R&D activity. [1]

Website BSE NSE
  • Market Cap ₹ 2,421 Cr.
  • Current Price ₹ 94.4
  • High / Low ₹ 108 / 61.2
  • Stock P/E 9.48
  • Book Value ₹ 82.5
  • Dividend Yield 2.33 %
  • ROCE 4.18 %
  • ROE 8.67 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Stock is trading at 1.14 times its book value
  • Company is expected to give good quarter
  • Company has been maintaining a healthy dividend payout of 17.3%

Cons

  • Tax rate seems low
  • Company has a low return on equity of 11.6% over last 3 years.
  • Earnings include an other income of Rs.44.2 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Realty Industry: Construction

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
14 29 21 20 19 18 22 37 31 37 37 32 39
11 25 17 17 16 15 17 26 20 24 26 22 28
Operating Profit 4 4 4 3 4 3 5 11 10 13 11 10 12
OPM % 27% 14% 20% 15% 19% 16% 25% 30% 34% 36% 30% 31% 30%
3 2 2 81 2 4 1 59 2 -9 3 48 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 2 2 2 2 2 2 3
Profit before tax 6 5 5 83 4 6 4 68 11 3 12 56 11
Tax % 16% 21% 20% 11% 4% 20% 11% 10% 2% -55% 14% 8% 9%
86 72 49 120 52 1 -19 115 46 48 44 91 61
EPS in Rs 3.33 2.80 1.91 4.68 2.02 0.04 -0.72 4.49 1.78 1.88 1.73 3.53 2.39
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2008 Mar 2009 Mar 2010 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
990 1,099 1,121 144 134 147 125 124 74 74 78 127 146
876 1,016 1,018 134 128 140 114 106 71 62 64 87 99
Operating Profit 114 83 103 10 6 7 11 18 3 11 14 40 46
OPM % 12% 8% 9% 7% 5% 5% 9% 15% 4% 15% 18% 32% 32%
67 7 16 21 25 25 37 29 93 10 89 54 44
Interest 35 42 32 1 0 0 0 0 0 0 0 0 1
Depreciation 33 38 43 6 6 5 4 3 3 4 5 7 8
Profit before tax 114 9 44 23 25 27 44 45 93 17 98 87 81
Tax % 1% -19% 10% -3% 2% -3% 5% 8% 0% 19% 12% 7%
112 11 40 107 235 145 163 213 329 343 222 191 245
EPS in Rs 0.81 0.39 1.48 3.99 8.78 5.45 6.10 8.30 12.82 13.35 8.65 7.42 9.53
Dividend Payout % 19% 51% 17% 4% 2% 4% 3% 2% 5% 2% 21% 30%
Compounded Sales Growth
10 Years: %
5 Years: 0%
3 Years: 20%
TTM: 34%
Compounded Profit Growth
10 Years: %
5 Years: 5%
3 Years: -15%
TTM: 78%
Stock Price CAGR
10 Years: 20%
5 Years: 22%
3 Years: -5%
1 Year: 54%
Return on Equity
10 Years: %
5 Years: 14%
3 Years: 12%
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2008 Mar 2009 Mar 2010 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 28 27 27 53 53 53 53 51 51 51 51 51 51
Reserves 314 304 311 474 750 858 1,032 1,157 1,367 2,246 2,445 2,027 2,068
423 475 408 0 9 0 0 0 0 0 0 0 5
181 209 251 91 64 81 73 57 53 112 135 127 145
Total Liabilities 946 1,015 997 619 875 992 1,159 1,266 1,471 2,409 2,632 2,205 2,270
367 405 393 169 146 171 179 209 225 265 297 321 344
CWIP 22 7 4 2 0 0 0 0 3 6 0 0 1
Investments 14 8 8 299 605 732 913 1,001 1,133 2,047 2,208 1,754 1,749
543 595 591 149 124 89 67 55 110 91 127 130 176
Total Assets 946 1,015 997 619 875 992 1,159 1,266 1,471 2,409 2,632 2,205 2,270

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2008 Mar 2009 Mar 2010 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
54 123 149 22 10 52 24 22 7 -2 -18 39
-225 -56 -24 5 -5 -47 -22 68 57 -35 19 7
39 -70 -118 -25 -5 -5 -3 -89 -6 -15 -6 -46
Net Cash Flow -133 -2 7 2 -0 -0 -1 1 57 -52 -5 -0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2008 Mar 2009 Mar 2010 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 85 71 63 122 76 54 74 40 44 69 71 67
Inventory Days 153 158 158 880 659 438 247 289 411 2,112 2,885
Days Payable 103 112 128 200 144 128 125 202 151 693 640
Cash Conversion Cycle 135 117 93 801 591 364 195 126 305 1,488 2,316 67
Working Capital Days 125 125 108 235 172 39 20 13 22 98 223 118
ROCE % 7% 10% 4% 4% 4% 4% 7% 1% 4% 4%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88% 70.88%
1.30% 1.23% 1.19% 1.12% 1.08% 0.83% 0.82% 0.70% 0.72% 0.85% 0.89% 1.07%
4.75% 4.89% 5.17% 4.69% 4.29% 4.12% 3.94% 3.94% 3.93% 3.40% 0.04% 0.04%
23.07% 23.00% 22.76% 23.31% 23.75% 24.16% 24.34% 24.48% 24.46% 24.87% 28.17% 28.02%
No. of Shareholders 77,20180,56178,38180,13583,00683,61283,63082,33981,73282,94794,01299,130

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings